艾伯维公司近日对美国卫生与公众服务部提起诉讼,抗议其旗下肉毒杆菌产品Botox被纳入《通胀削减法案》框架下的医疗保险药品价格谈判清单。此次诉讼直指联邦政府药品定价政策的核心争议,凸显出制药企业与监管机构在控制医疗成本与保障创新回报之间的激烈博弈。
艾伯维公司近日对美国卫生与公众服务部提起诉讼,抗议其旗下肉毒杆菌产品Botox被纳入《通胀削减法案》框架下的医疗保险药品价格谈判清单。此次诉讼直指联邦政府药品定价政策的核心争议,凸显出制药企业与监管机构在控制医疗成本与保障创新回报之间的激烈博弈。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.